FY2025 Earnings Forecast for MNPR Issued By Chardan Capital

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings estimates for Monopar Therapeutics in a research report issued on Tuesday, June 24th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings per share of ($2.02) for the year. Chardan Capital currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.87) EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27.

Several other equities research analysts have also recently issued reports on MNPR. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Finally, Piper Sandler restated an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $56.50.

Monopar Therapeutics Trading Down 4.0%

Monopar Therapeutics stock opened at $33.60 on Friday. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The stock has a market cap of $205.63 million, a P/E ratio of -9.66 and a beta of 0.99. The company has a 50-day moving average price of $36.75 and a 200 day moving average price of $34.83.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently made changes to their positions in MNPR. Goldman Sachs Group Inc. purchased a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $673,000. Jane Street Group LLC purchased a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $377,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $328,000. Affinity Asset Advisors LLC purchased a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $2,257,000. Finally, AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $44,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares in the company, valued at $28,778,925. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 20.50% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.